1. Curing Cardiac Arrhythmias

2. Becoming the world leader in magnetic
targeted delivery of nanomedicines
Innovative nano-bio-medical delivery platform
First class multidisciplinary team
Physiological solution for curing atrial fibrillation
2

3. Impact of Atrial Fibrillation
Most common cardiac arrhythmia
worldwide
5 Million office visits/yr
Significantly increased risk of stroke
3

4. Novel Therapy for Atrial Fibrillation
Target neural ganglia
Electromagnetic force directs nanoparticles
Curative targeted therapy
Very low medical risk
Highly efficient procedure
4

5. The Products
Magnetic Workstation
Electromagnet
X-Y-Z table
5

6. The Products
Nanoformulation Kit
Superparamagnetic
particles
Neurotoxin therapeutic
agent
Biocompatible polymer
(PLGA)
6

7. Market Size
2.5 million patients, 2011
No. of patients estimated to triple
by 2016
$16 B annual costs related to AF
7

8. Competition
3M
Medtronic
Medication Catheter Boston
Bard Ablation Scientific
Sanofi Abbott
J&J
8

9. Revenue Model & Product Pricing
• Selling a Magnetic Work Station ~$100,000 per station
• Selling magnetic nanoparticles Nanoformulation Kit for each
procedure ~$800 per procedure
Main revenue generator will be the Nano-
formulation Kit for each procedure
9

10. Customer Acquisition Plan
• In-house marketing and sales personal to
establish initial sales
• Addressing opinion leaders to get
recognition and exposure
• Forming cooperative agreements with
market leaders to increase sales
• Launching product in Europe followed by
USA
10

11. Timeline
Initial Clinical PMA
Animal Studies Trial - CE Submission
2012-2013 2013 2013-2014 2014-2015 2016 -2017
Multi Site
Clinical Trials
CE application Initial Sales
Patent Applications Developing Animal
Proof of Concept Prototype Studies
In
Progress
11

12. The Team
• Alex Harel – President & CEO – Founding and managing several
start-up companies in Israel, including BBMS Ltd.
• Kenneth J. Dormer, MS, PhD – Chairman of Advisory Board - Professor of
Physiology, Senior Scientist Heart Rhythm Institute, OUHSC.
• Sunny Po, MD, PhD – Primary Medical Investigator; Member of Advisory
Board - Director of Clinical Electrophysiology, Associate Director, Heart Rhythm
Institute, OUHSC.
• Benjamin J. Scherlag, PhD – Investigator ; Member of Advisory Board -
Regents Professor of Medicine/Cardiology, George Lynn Cross Professor of
Research, OUHSC.
• Dr. Udi Katznelson, PhD– Investigator - Ph.D. in Physics, Tel-Aviv University;
inventor and the designer of many magnetic and MRI products.
Collaborations:
OUHSC, UT - Arlington, UOM, OSU, Center for Integrated Nanotechnologies -
Sandia National Laboratories, Albuquerque, NM
12

13. Becoming the world leader in magnetic
targeted delivery of nanomedicines
Innovative, Safer, Econ
Stroke-Prone, Current Treatments
omical, Curative
Debilitating Arrhythmia Costly, Risky, Limited
Targeted Therapy
Alex Harel - CEO Ken Dormer – Chief Scientist
Cell: 405-445 7888 Cell: 405-706 3711
alex@nanomed-systems.com ken@nanomed-systems.com
13